Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction

BACKGROUND: Pulmonary hypertension (PH) is common in patients with left heart failure (HF), especially those with FIF and preserved ejection fraction (HFpEF). However, there is limited data on risk stratification in these patients. METHODS: Baseline clinical and hemodynamic variables of 339 patients with World Health Organization (WHO) Group 2 PH, 90% of whom had HFpEF, were studied to derive a multivariate Cox proportional hazards model. A simplified prognostic risk score was created based on the outcome of all-cause mortality. Nine predictors, significant after stepwise multivariable regression (p < 0.05), were used to create the risk score. Components of the risk score were functional class, diastolic blood pressure, pulmonary artery saturation, interstitial lung disease, hypotension on initial presentation, right ventricular hypertrophy, diffusion capacity of the lung for carbon monoxide, and 2 serum creatinine variables (<= 0.9 mg/di and >= 1.4 mg/dl). RESULTS: Overall 2-year survival was 73.8% +/- 2.4% in the derivation cohort, and 87.5% +/- 2.3%, 66.4% +/- 4.9%, and 24.4% +/- 6.7% for risk scores of 0 to 2, 3 to 4, and 5+, respectively (p < 0.0001 for the trend), with a C-index of 0.76 (95% confidence interval [CI], 0.71-0.81). The risk score was validated in 2 independent PH-HFpEF cohorts: 179 patients with a C-index of 0.68 (95% Cl. 0.55-0.80) and 117 patients with a C-index of 0.68 (95% Cl, 0.53-0.83). For the 3 cohorts combined (N = 635), the overall C-index was 0.72 (95% CI 0.68-0.76). In all 3 cohorts individually and in the 3 cohorts combined, the risk score predicted death (hazard ratio, 1.4-1.6; p < 0.01). CONCLUSIONS: Several clinical factors independently predict death in PH-HFpEF confirmed by validation. A novel risk score composed of these factors can be used to determine prognosis and may be useful in making therapeutic decisions. J Heart Lung Transplant 2012;31:467-77 (C) 2012 International Society for Heart and Lung Transplantation. All rights reserved.